Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Maintenance Zanzalintinib and Durvalumab in Patients With Advanced Hepatocellular Cancer After Induction Tremelimumab Plus Durvalumab

NCT07226063 is registered in ClinicalTrials.gov with Amit Mahipal as lead sponsor.

NCT NCT07226063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07226063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Maintenance Zanzalintinib and Durvalumab in Patients With Advanced Hepatocellular Cancer After Induction Tremelimumab Plus Durvalumab
Lead sponsor
Amit Mahipal
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
August 31, 2028
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, liver cancer